{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T22:43:23Z","timestamp":1776984203098,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-026-04354-w","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:55:02Z","timestamp":1773464102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose mifepristone for the management of refractory heavy menstrual bleeding in women with bleeding disorders: a retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaolin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehui","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruxue","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huina","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"4354_CR1","first-page":"604","volume-title":"Internal Medicine","author":"J Ge","year":"2018","unstructured":"Ge J, Xu Y, Wang C. Internal Medicine. 9th ed. Beijing: People\u2019s Medical Publishing House; 2018. pp. 604\u201311.","edition":"9"},{"key":"4354_CR2","unstructured":"National Institute for Health and Care Excellence. Heavy menstrual bleeding:assessment and management. 2018. https:\/\/www.nice.org.uk\/guidance\/ng88. Accessed 02 Dec 2019."},{"key":"4354_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijgo.2014.09.027","volume":"128","author":"IS Fraser","year":"2015","unstructured":"Fraser IS, Mansour D, Breymann C, Hoffman C, Mezzacasa A, Petraglia F. Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey. Int J Gynaecol Obstet. 2015;128:196\u2013200.","journal-title":"Int J Gynaecol Obstet"},{"key":"4354_CR4","unstructured":"National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. NICE guideline [NG88]. 2018. Available at: https:\/\/www.nice.org.uk\/guidance\/ng88. Accessed 21 Aug 2019."},{"issue":"6 suppl","key":"4354_CR5","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/j.contraception.2007.01.005","volume":"75","author":"RA Kadir","year":"2007","unstructured":"Kadir RA, Chi C. Levonorgestrel intrauterine system: bleeding disorders and anticoagulant therapy. Contraception. 2007;75(6 suppl):S123.","journal-title":"Contraception"},{"key":"4354_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.contraception.2010.07.010","volume":"83","author":"C Chi","year":"2011","unstructured":"Chi C, Huq FY, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception. 2011;83:242.","journal-title":"Contraception"},{"key":"4354_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1083-3188(98)70101-9","volume":"11","author":"YR Smith","year":"1998","unstructured":"Smith YR, Quint EH, Hertzberg RB. Menorrhagia in adolescents requiring hospitalization. J Pediatr Adolesc Gynecol. 1998;11:13.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"4354_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s004040100192","volume":"266","author":"E Oral","year":"2002","unstructured":"Oral E, Ca!gdas\u00b8 A, Gezer A, et al. Hematological abnormalities in adolescent menorrhagia. Arch Gynecol Obstet. 2002;266:72.","journal-title":"Arch Gynecol Obstet"},{"key":"4354_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0002-9378(81)90009-0","volume":"139","author":"EA Claessens","year":"1981","unstructured":"Claessens EA, Cowell CA. Acute adolescent menorrhagia. Am J Obstet Gynecol. 1981;139:277.","journal-title":"Am J Obstet Gynecol"},{"key":"4354_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/01.AOG.0000148889.15061.fb","volume":"105","author":"CS Philipp","year":"2005","unstructured":"Philipp CS, Faiz A, Dowling N, et al. Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol. 2005;105:61.","journal-title":"Obstet Gynecol"},{"key":"4354_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jpag.2013.06.003","volume":"26","author":"V Seravalli","year":"2013","unstructured":"Seravalli V, Linari S, Peruzzi E, et al. Prevalence of hemostatic disorders in adolescents with abnormal uterine bleeding. J Pediatr Adolesc Gynecol. 2013;26:285.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"4354_CR12","unstructured":"Shi D. Clinical observation of mifepristone in the treatment of dysfunctional uterine bleeding during menopause. Practical Electronic J Mater Fetal Med. 2019;6(9):71+74."},{"issue":"8","key":"4354_CR13","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/humrep\/dep100","volume":"24","author":"M Engman","year":"2009","unstructured":"Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009;24(8):1870\u20139.","journal-title":"Hum Reprod"},{"key":"4354_CR14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ejogrb.2024.10.059","volume":"303","author":"X Yin","year":"2024","unstructured":"Yin X, He L, Xu H, Lou S, Tan Y, Wang Y, Luo X, Huang Y. Efficacy and safety of different doses of mifepristone in the treatment of uterine fibroids: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2024;303:302\u20139.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"4354_CR15","first-page":"9","volume":"12","author":"J Gu","year":"2012","unstructured":"Gu J, Yang K, Zhang L, et al. Systematic evaluation of the efficacy and safety of mifepristone in the treatment of dysfunctional uterine bleeding during peri-menopause. Chin J Evidence-Based Med. 2012;12(4):9.","journal-title":"Chin J Evidence-Based Med"},{"key":"4354_CR16","unstructured":"Pi Huichun L, Jinzhi. Effects of blood platelets and prothrombin time on mifepristone. J Prim Med Res. 2006;(05):211\u20132. (in Chinese)."},{"issue":"08","key":"4354_CR17","first-page":"1430","volume":"34","author":"L Wei","year":"2013","unstructured":"Wei L. The effect of mifepristone on blood coagulation function of early pregnant women in medical abortion. Jilin Med J. 2013;34(08):1430\u20131. (in Chinese).","journal-title":"Jilin Med J"},{"key":"4354_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/hae.12886","volume":"22","author":"S Halimeh","year":"2016","unstructured":"Halimeh S, Rott H, Kappert G. PBAC score: an easy-to-use tool to predict coagulation disorders in women with idiopathic heavy menstrual bleeding. Haemophilia. 2016;22:208\u201344.","journal-title":"Haemophilia"},{"issue":"8","key":"4354_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1471-0528.1990.tb16249.x","volume":"97","author":"JM Higham","year":"1990","unstructured":"Higham JM, O\u2019Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97(8):734.","journal-title":"Br J Obstet Gynaecol"},{"issue":"12","key":"4354_CR20","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/j.1471-0528.2011.03057.x","volume":"118","author":"H Pattison","year":"2011","unstructured":"Pattison H, Daniels JP, Kai J, Gupta JK. The measurement properties of the menorrhagia multi-attribute quality-of-life scale: a psychometric analysis. BJOG. 2011;118(12):1528\u201331.","journal-title":"BJOG"},{"issue":"4","key":"4354_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.contraception.2020.05.009","volume":"102","author":"RR Campos","year":"2020","unstructured":"Campos RR, Ba\u00eata T, Silva-Filho A, Rezende SM, Rocha ALL. Use of a levonorgestrel 52-mg intrauterine system in the control of abnormal uterine bleeding in women with inherited bleeding disorders. Contraception. 2020;102(4):254\u20138.","journal-title":"Contraception"},{"issue":"2","key":"4354_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jpag.2021.11.002","volume":"35","author":"PS Huguelet","year":"2022","unstructured":"Huguelet PS, Laurin JL, Thornhill D, Moyer G. Use of the Levonorgestrel Intrauterine System to Treat Heavy Menstrual Bleeding in Adolescents and Young Adults with Inherited Bleeding Disorders and Ehlers-Danlos Syndrome. J Pediatr Adolesc Gynecol. 2022;35(2):147\u2013e1521.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"4354_CR23","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/hae.12184","volume":"19","author":"E Rimmer","year":"2013","unstructured":"Rimmer E, Jamieson MA. Malposition and expulsion of the levonorgestrel intrauterine system among women with inherited bleeding disorders. Haemophilia. 2013;19:933.","journal-title":"Haemophilia"},{"key":"4354_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.contraception.2021.09.001","volume":"105","author":"RM Furlani","year":"2022","unstructured":"Furlani RM, Garcia E, Castro S, Machado HC, Bahamondes L, Monteiro I. Expulsion rates of the levonorgestrel 52\u00a0mg intrauterine system are similar among women with heavy menstrual bleeding and users for contraception. Contraception. 2022;105:75\u20139.","journal-title":"Contraception"},{"issue":"5","key":"4354_CR25","doi-asserted-by":"publisher","first-page":"bnaa012","DOI":"10.1210\/endrev\/bnaa012","volume":"41","author":"MS Islam","year":"2020","unstructured":"Islam MS, Afrin S, Jones SI, Segars J. Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility. Endocr Rev. 2020;41(5):bnaa012.","journal-title":"Endocr Rev"},{"issue":"2","key":"4354_CR26","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1111\/jcmm.14866","volume":"24","author":"X Che","year":"2020","unstructured":"Che X, Wang J, He J, et al. A new trick for an old dog: The application of mifepristone in the treatment of adenomyosis. J Cell Mol Med. 2020;24(2):1724\u201337.","journal-title":"J Cell Mol Med"},{"issue":"7","key":"4354_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.humpath.2010.11.003","volume":"42","author":"J Fiscella","year":"2011","unstructured":"Fiscella J, Bonfiglio T, Winters P, et al. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol. 2011;42(7):947\u201353.","journal-title":"Hum Pathol"},{"issue":"5","key":"4354_CR28","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1210\/jc.2003-031945","volume":"89","author":"N Narvekar","year":"2004","unstructured":"Narvekar N, Cameron S, Critchley HO, et al. Low- dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab. 2004;89(5):2491\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4354_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jrhm.2015.09.001","volume":"2","author":"JL Carbonell","year":"2016","unstructured":"Carbonell JL, River\u00f3n AM, Leonard Y, Gonz\u00e1lez J, Heredia B, S\u00e1nchez C. Mifepristone 2.5, 5, 10\u00a0mg versus placebo in the treatment of endometriosis. J Reprod Health Med. 2016;2(1):17\u201325.","journal-title":"J Reprod Health Med"},{"issue":"6","key":"4354_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/humupd\/dmm023","volume":"13","author":"FM Horne","year":"2007","unstructured":"Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update. 2007;13(6):567\u201380.","journal-title":"Hum Reprod Update"},{"issue":"4","key":"4354_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/13697137.2017.1386650","volume":"21","author":"N Chabbert-Buffet","year":"2018","unstructured":"Chabbert-Buffet N, Kolanska K, Dara\u00ef E, Bouchard P. Selective progesterone receptor modulators: current applications and perspectives. Climacteric. 2018;21(4):375\u20139.","journal-title":"Climacteric"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-026-04354-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04354-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04354-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T22:28:04Z","timestamp":1776983284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-026-04354-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4354"],"URL":"https:\/\/doi.org\/10.1186\/s12905-026-04354-w","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in strict compliance with the ethical principles for medical research involving human participants as stipulated in the World Medical Association Declaration of Helsinki (revised at the 75th WMA General Assembly, Helsinki, Finland, October 2024). The study protocol was approved by the Medical Ethics Committee of Peking University People\u2019s Hospital, ethics number (2021PHB093-001). All participants were informed of the purpose of the study and given verbal informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"n\/a.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}